Adam Farber
Managing Director & Senior Partner
Boston
Adam Farber is both the global leader of the Health Care practice and a core member of the Operations practice at Boston Consulting Group.
Since he joined BCG in 1998, Adam's client work has covered multiple sectors in health care, including biopharma and medtech, payers, providers, and global health.
Adam's client work has ranged from strategy definition to business model/organization changes, growth and innovation, operations/supply chain transformation, and applying digital and analytics to drive business acceleration.
Adam has authored articles for the industry journal Pharmaceutical Executive, and he has contributed a chapter to the BCG book, Own the Future: 50 Ways to Win from The Boston Consulting Group.
Prior to joining BCG, Adam worked at the management consultancy Lochridge & Company.
Three strategies for fighting the coronavirus and restarting economies have emerged. The most popular one is the most unstable.
In their response to COVID-19, pharma and medtech companies have been true to their purpose. They now face questions that go beyond addressing the virus itself.
Traditional leadership models are out of date. It’s time to do things differently.
To succeed in both high- and low-growth markets, companies must rethink every aspect of their operations, BCG contends in a report published jointly with Knowledge@Wharton.
Lean practices have much to offer biopharma—but realizing those benefits hinges on proper implementation. The keys are an incremental approach and engagement of frontline staff.
